Showing 1531-1540 of 2656 results for "".
- American Medical Association’s New President a ‘Passionate Defender of the Independent Physician’https://modernod.com/news/american-medical-associations-new-president-a-passionate-defender-of-the-independent-physician/2477875/Susan Bailey, MD, the new president of the American Medical Association (AMA), called for physicians to advocate at the highest levels of government and insurance companies for support needed “to sustain private practice during a pandemic that threatens its very survival,” according t
- Early Data Show Moderna’s COVID-19 Vaccine Generates Immune Responseshttps://modernod.com/news/first-covid-19-vaccine-tested-in-the-us-shows-promise-in-data-from-eight-people/2477791/Moderna reported positive interim data from a phase 1 study of its vaccine candidate against SARS-CoV-2, with results showing that mRNA-1273 elicited neutralizing antibody titer levels in all eight initial participants in the low- and mid-dose cohorts, reaching or exceeding levels generally seen
- FDA Approves Quidel’s Sofia 2, First Antigen Test to Help in the Rapid Detection of COVID-19https://modernod.com/news/quidel-receives-emergency-authorization-for-rapid-antigen-covid-19-diagnostic-assay/2477735/Quidel, which makes diagnostic tests for a variety of conditions including acute conjunctivitis and dry eye disease, announced that it has received Emergency Use Authorization (EUA) from the FDA to market its Sofia 2
- WHO Accidently Leaks Disappointing Results of Chinese Clinical Trial Testing Gilead’s Remdesivir in Severe COVID-19https://modernod.com/news/who-accidently-leaks-disappointing-results-of-chinese-clinical-trial-testing-gileads-remdesivir-in-severe-covid-19/2477645/According to a draft document published in error by the World Health Organization (WHO), Gilead Sciences’ remdesivir failed to improve the condition of patients with severe COVID-19 participating in a Chinese clinical trial, nor was the drug found to reduce the virus’ presence in the
- Lancet Neurology Publishes Pivotal Phase 3 Data for Genentech’s Satralizumab for NMOSDhttps://modernod.com/news/lancet-neurology-publishes-pivotal-phase-3-data-for-genentechs-satralizumab-for-nmosd/2477640/Lancet Neurology published full pivotal phase 3 clinical data on investigational medicine satralizumab as a monotherapy for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating central nervous system disease that is commonly misdiagnosed as multiple scler
- ‘A Disaster’: Roche CEO’s Verdict on Some COVID-19 Antibody Testshttps://modernod.com/news/a-disaster-roche-ceos-verdict-on-some-covid-19-antibody-tests/2477636/Some blood tests being marketed to tell people if they have had the new coronavirus are a “disaster,” Roche Chief Executive Severin Schwan said on Wednesday as he prepares to launch the drugmaker’s own antibody test next month, according to a Reuters report. </
- HHS: Here’s How Remaining $70B in COVID-19 Funding Will Be Distributed to Providershttps://modernod.com/news/hhs-heres-how-remaining-70b-in-covid-19-funding-will-be-distributed-to-providers/2477633/The Trump administration has laid out a plan for how to disperse the remaining $70 billion to providers struggling financially due to the COVID-19 outbreak, according to a FierceHealthcare
- FDA Grants Priority Review Approval For Regeneron’s REGN-EB3 to Treat Ebolahttps://modernod.com/news/fda-crants-for-priority-review-approval-for-regenerons-regn-eb3-to-treat-ebola/2477599/Regeneron Pharmaceuticals announced that the FDA has accepted for priority review a new biologics license application (BLA) for REGN-EB3, an investigational triple antibody cocktail treatment for Ebola virus infection. The target action date for the FDA decision is October 25, 2020.
- EU Body Backs Compassionate Use of Gilead’s Remdesivir for COVID-19https://modernod.com/news/eu-body-backs-compassionate-use-of-gileads-remdesivir-for-covid-19/2479531/The European Medicines Agency (EMA) said its Committee for Medicinal Products for Human Use (CHMP) recommended compassionate use of Gilead Sciences’ investigational antiviral remdesivir to treat COVID-19. However, the agency cautioned that while remdesivir has been shown to be active agains
- FDA Approves Genentech’s Clinical Trial for Actemra to Treat Hospitalized Patients With Severe COVID-19 Pneumoniahttps://modernod.com/news/fda-approves-genentechs-clinical-trial-for-actemra-to-treat-hospitalized-patients-with-severe-covid-19-pneumonia/2477442/Genentech announced Monday that the FDA has approved a randomized, double-blind, placebo-controlled phase 3 clinical trial in collaboration with the Biomedical Advanced Research and Development Authority (BARDA) to evaluate the safety and efficacy of intravenous Actemra (tocilizumab) plus standar